5/24/2019, 7:18 PM (Source: TeleTrader)
more TeleTrader news


Chart for: Novartis AG

Novartis jumps on FDA approval of gene therapy

Shares of Swiss pharmaceutical company Novartis International AG surged on Friday after the United States Food and Drug Administration approved its $2.3 million gene therapy for spinal muscular atrophy.

The treatment named Zolgensma is designed to address the genetic root cause of SMA, a rare neuromuscular disorder which leads to muscle wasting.

"Zolgensma is a historic advance for the treatment of SMA and a landmark one-time gene therapy. Our goal is to ensure broad patient access to this transformational medicine and to share value with the healthcare system," Novartis CEO Vas Narasimhan said in a statement.

Novartis jumped 4.29% to $88.06 per share at 11:11 am ET following the news.

Breaking the News / JC